search
Back to results

Impact of Providing Medical Records in a Patient-Centered, Community Pharmacy Based, HIV Care Model (HIV-MOI) (HIV-MOI)

Primary Purpose

HIV/AIDS, Diabetes Mellitus, Type 2, Hypertension

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Medication optimization intervention
Sponsored by
University of North Texas Health Science Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV/AIDS focused on measuring HIV, AIDS, Diabetes Melllitus, Type 2, Hypertension, Pharmacist, Medication optimization, Medication Therapy Management, MTM

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years of age or older
  • African-American
  • HIV positive
  • At least one of the following: hypertension or diabetes type 2

Exclusion Criteria:

  • Pregnant (at screening, may enroll 6 months post-delivery)
  • Have a life expectancy < 2 years
  • Refusal to provide medical record release

Sites / Locations

  • Crystal Hodge
  • University of North Texas Health Science Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Medication Optimization Intervention

Medication Optimization Control

Arm Description

This group will represent those participants whose medical records have been provided to the pharmacist.

This group will represent those participants whose medical records have not been provided to the pharmacist.

Outcomes

Primary Outcome Measures

Diabetes mellitus
Participants will be assessed for improvement in clinical markers associated with diabetes
Hypertension
Participants will be assessed for improvement in clinical markers associated with hypertension.

Secondary Outcome Measures

Full Information

First Posted
February 12, 2018
Last Updated
June 5, 2023
Sponsor
University of North Texas Health Science Center
Collaborators
University of California, San Francisco, University of Minnesota, Walgreens, A Boots Alliance
search

1. Study Identification

Unique Protocol Identification Number
NCT03437694
Brief Title
Impact of Providing Medical Records in a Patient-Centered, Community Pharmacy Based, HIV Care Model (HIV-MOI)
Acronym
HIV-MOI
Official Title
Assessing the Impact of Providing Pharmacists With Medical Records in a Patient-Centered, Community Pharmacy-Based, HIV Care Model
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 3, 2018 (Actual)
Primary Completion Date
October 31, 2022 (Actual)
Study Completion Date
May 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of North Texas Health Science Center
Collaborators
University of California, San Francisco, University of Minnesota, Walgreens, A Boots Alliance

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a clinical trial. The purpose of this clinical trial is to see if study participants have better health outcomes if their pharmacist has access to their medical records. The study will take place primarily in Fort Worth and Dallas, Texas. The trial will enroll adult, African-Americans with HIV. Study participants must also have either diabetes, high blood pressure or they may have both. Study participants will agree to have their medical records from all of their health providers released to UNTHSC. UNTHSC will provide the study pharmacist the medical records for half of the participants. Using the medical records, the study pharmacist will provide 'enhanced' patient counseling services to half of the participants. This enhanced service is called 'medication optimization'. For half of the participants that the study pharmacist does not see the medical records, they will receive usual and customary patient counseling. Not seeing the medical records is considered standard of care. In both groups, the counseling frequency will be based on the participant's needs but the study pharmacist will contact every participant to check on them at least every 90 days. These visits will happen for 2 years. The two groups will be compared to see if those participants having medical information supported medication optimization have better health than those getting routine, the standard of care medication optimization.
Detailed Description
This study examines HIV medication optimization (HIV-MOI) in a prospective, randomized (1:1 HIV-MOI: standard of care), clinical trial, comparing disease-specific clinical and humanistic outcomes in up to 200 adult African-Americans with HIV (1:1 men: women) and either diabetes mellitus type 2 (DM) and/or hypertension (HTN). Data will be collected from individual participants for a 2 year period. Once properly screened, consented and enrolled, medical records from participant's medical provider(s) will be obtained. Upon receipt of the medical records, research team personnel (working closely with the project biostatistician) will provide medical information only for those participants randomized to receive HIV-MOI to the study pharmacist. The study pharmacist then assesses the information to determine the clinical effectiveness and appropriateness of the current medical plan's medications. Upon completion, the study pharmacist will develop a prioritized medication problem list, create a plan, discuss/collaborate with the medical provider/healthcare team member as needed and then conduct the initial HIV-MOI visit with the patient. At the initial visit, an individualized care plan would be finalized with study participant input. Also at the initial HIV-MOI visit, the patient should receive an accurate (and reconciled with medical providers) personal medication record (PMR). Participants should also receive an individualized care plan called a medication action plan (MAP). The MAP can include non-pharmacological instructions and education. This may be guided in part by qualitative survey data obtained as part of the study visit. Follow-up visits will occur (ideally) not less than quarterly. Follow-up visits may occur face-to-face or using telecommunication methods. The study pharmacist will only be provided the medical information for the intervention group. Standard of care for pharmacists is not having access to medical information when providing HIV-MOI. Extracted data and study obtained data will be entered into the study database for analyses.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV/AIDS, Diabetes Mellitus, Type 2, Hypertension
Keywords
HIV, AIDS, Diabetes Melllitus, Type 2, Hypertension, Pharmacist, Medication optimization, Medication Therapy Management, MTM

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be randomized in a 1:1 ratio to either the intervention or control group.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
130 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Medication Optimization Intervention
Arm Type
Experimental
Arm Description
This group will represent those participants whose medical records have been provided to the pharmacist.
Arm Title
Medication Optimization Control
Arm Type
Active Comparator
Arm Description
This group will represent those participants whose medical records have not been provided to the pharmacist.
Intervention Type
Other
Intervention Name(s)
Medication optimization intervention
Other Intervention Name(s)
medication therapy management
Intervention Description
Pharmacists will engage participants in medication therapy management either with access to the medical records (intervention) or without access (control).
Primary Outcome Measure Information:
Title
Diabetes mellitus
Description
Participants will be assessed for improvement in clinical markers associated with diabetes
Time Frame
6 months
Title
Hypertension
Description
Participants will be assessed for improvement in clinical markers associated with hypertension.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years of age or older African-American HIV positive At least one of the following: hypertension or diabetes type 2 Exclusion Criteria: Pregnant (at screening, may enroll 6 months post-delivery) Have a life expectancy < 2 years Refusal to provide medical record release
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Crystal K Hodge, PharmD
Organizational Affiliation
UNTHSC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Crystal Hodge
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76107
Country
United States
Facility Name
University of North Texas Health Science Center
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76107
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Impact of Providing Medical Records in a Patient-Centered, Community Pharmacy Based, HIV Care Model (HIV-MOI)

We'll reach out to this number within 24 hrs